FDA Approves Tralokinumab Autoinjector Pen for Adults With Moderate to Severe AD
The U.S. Food and Drug Administration (FDA) has given its nod to tralokinumab-ldrm (Adbry, Leo Pharma) 300mg single-dose autoinjector for adults with moderate to severe atopic dermatitis (AD). Tralokinumab-ldrmis is a high-affinity fully human monoclonal antibody developed to bind to and inhibit the interleukin (IL)-13 cytokine. The new autoinjector is another option for adult patients […]